Genetic profile of 22 pancreatic carcinoma cell lines
暂无分享,去创建一个
F. Real | M. Löhr | A. Scarpa | N. Lemoine | C. Bassi | T. Gress | B. Sipos | G. Klöppel | H. Kalthoff | P. Moore | C. Sorio | H. Ungefroren | S. Orlandini
[1] G. Gaviraghi,et al. Successful xenografting of cryopreserved primary pancreatic cancers , 2001, Virchows Archiv.
[2] S. Kern,et al. Homozygous deletions inactivate DCC, but not MADH4/DPC4/SMAD4, in a subset of pancreatic and biliary cancers , 2000, Genes, chromosomes & cancer.
[3] M V Chernov,et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. , 1999, Science.
[4] K. Kinzler,et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.
[5] R. Hruban,et al. Novel homozygous deletions of chromosomal band 18q22 in pancreatic adenocarcinoma identified by STS marker scanning , 1999, Genes, chromosomes & cancer.
[6] A. Schudy,et al. Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas. , 1999, Cancer letters.
[7] A. Andrén-sandberg,et al. Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer , 1999, Genes, chromosomes & cancer.
[8] G. Capellá,et al. Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cells , 1998, Oncogene.
[9] M. Taniwaki,et al. Rare Alteration of Genomic Structure or Expression of the DPC4 Gene in Myelogenous Leukemias , 1998, Acta Haematologica.
[10] W. Schmiegel,et al. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. , 1998, Cancer research.
[11] J. Yokota,et al. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma. , 1997, Cancer research.
[12] D. Slamon,et al. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas , 1997, Oncogene.
[13] S. Goodman,et al. Tumor-suppressive pathways in pancreatic carcinoma. , 1997, Cancer research.
[14] S. Kern,et al. DPC4 gene mutation in colitis associated neoplasia. , 1997, Gut.
[15] G. Capellá,et al. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. , 1996, Cancer research.
[16] Suna Wang,et al. Infrequent DPC4 gene mutation in esophageal cancer, gastric cancer and ulcerative colitis-associated neoplasms. , 1996, Oncogene.
[17] S. Kern,et al. Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. , 1996, Cancer research.
[18] J. Herman,et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[19] Scott E. Kern,et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers , 1996, Nature Genetics.
[20] R. Lotan,et al. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. , 1996, Cancer research.
[21] Kathleen R. Cho,et al. DPC4 gene in various tumor types. , 1996, Cancer research.
[22] Scott E. Kern,et al. DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.
[23] R. Hruban,et al. Allelotype of pancreatic adenocarcinoma using xenograft enrichment. , 1995, Cancer research.
[24] J. Lloreta,et al. New pancreas cancers cell lines that represent distinct stages of ductal differentiation. , 1995, Laboratory investigation; a journal of technical methods and pathology.
[25] A. Klein-Szanto,et al. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. , 1994, Cancer research.
[26] R. Hruban,et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.
[27] R. Hruban,et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. , 1994, Cancer research.
[28] C Caldas,et al. Allelotype of pancreatic adenocarcinoma. , 1994, Cancer research.
[29] G. Capellá,et al. Pancreatic cancer in europe: Ki‐ras gene mutation pattern shows geographical differences , 1994, International journal of cancer.
[30] S. Hirohashi,et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. , 1993, The American journal of pathology.
[31] G. Lauer,et al. p53 and K-RAS alterations in pancreatic epithelial cell lesions. , 1993, Oncogene.
[32] M. Iannuzzi,et al. A cystic fibrosis pancreatic adenocarcinoma cell line. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[33] S. Singletary,et al. Establishment of a New Human Pancreatic Adenocarcinoma Cell Line, MDAPanc‐3 , 1990, Pancreas.
[34] T. Shimauchi,et al. The tumor cells (FA-6) established from a pancreatic cancer associated with humoral hypercalcemia of malignancy: a simultaneous production of parathyroid hormone-like activity and transforming growth factor activity. , 1989, Endocrinologia japonica.
[35] G. Fleuren,et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. , 1988, Nucleic acids research.
[36] D. Shibata,et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.
[37] T. Sugimura,et al. Establishment of a human pancreatic adenocarcinoma cell line (PSN-1) with amplifications of both c-myc and activated c-Ki-ras by a point mutation. , 1986, Biochemical and biophysical research communications.
[38] N. Yamaguchi,et al. Establishment and characterization of a carcinoembryonic antigen (CEA)‐producing cell line from a human carcinoma of the exocrine pancreas , 1983, Cancer.
[39] M. D. Turner,et al. Establishment and characterization of two human pancreatic cancer cell lines tumorigenic in athymic mice. , 1982, Cancer research.
[40] M. Borowitz,et al. Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. , 1982, Cancer research.
[41] J. Hermon-Taylor,et al. Establishment and characterization of primary human pancreatic carcinoma in continuous cell culture and in nude mice. , 1979, British Journal of Cancer.
[42] A. Yunis,et al. Human pancreatic carcinoma (mia paca‐2) in continuous culture: Sensitivity to asparaginase , 1977, International journal of cancer.
[43] M. Lieber,et al. Establishment of a continuous tumor‐cell line (PANC‐1) from a human carcinoma of the exocrine pancreas , 1975, International journal of cancer.
[44] R. Hruban,et al. Loss of Expression of Dpc 4 in Pancreatic Intraepithelial Neoplasia : Evidence That DPC 4 Inactivation Occurs Late in Neoplastic Progression 1 , 2000 .
[45] R. Klinke,et al. A Chemical Inhibitor of p 53 That Protects Mice from the Side Effects of Cancer Therapy , 1999 .
[46] T. Mitsudomi,et al. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. , 1996, Cancer research.
[47] N. Lemoine,et al. Ki-ras oncogene activation in preinvasive pancreatic cancer. , 1992, Gastroenterology.
[48] A. Klein-Szanto,et al. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. , 1992, Oncogene.
[49] T. Iwamura,et al. Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. , 1987, Japanese journal of cancer research : Gann.